Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and

J T-J Huang1, L Wang, S Prabakaran

  • 1Institute of Biotechnology, University of Cambridge, Cambridge, UK.

Molecular Psychiatry
|October 17, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring Implicit Emotional Associations With Death in Patients With Current Suicidal Ideation: Results From Novel Attitude Implicit Association Tests for Suicide.

Suicide & life-threatening behavior·2025
Same author

First clinical implementation of a highly efficient daily online adapted proton therapy (DAPT) workflow.

Physics in medicine and biology·2024
Same author

Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis.

Brain, behavior, and immunity·2023
Same author

Radiotherapy dose and survival outcomes in human papillomavirus positive oropharyngeal cancer.

The Journal of laryngology and otology·2020
Same author

Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells.

Endocrine-related cancer·2020
Same author

Aircraft soot from conventional fuels and biofuels during ground idle and climb-out conditions: Electron microscopy and X-ray micro-spectroscopy.

Environmental pollution (Barking, Essex : 1987)·2019
Same journal

Cross-ancestry pleiotropic analysis of imaging-derived phenotypes enhances risk stratification of depression.

Molecular psychiatry·2026
Same journal

Shared genetic architecture of schizophrenia and Alzheimer's disease and related dementias implicates 16p11.2 and lifespan brain vulnerability.

Molecular psychiatry·2026
Same journal

The neurodevelopmental spectrum: phenotypic architecture, etiology, predictive utility, and specificity across development.

Molecular psychiatry·2026
Same journal

Towards ecological psychiatry: The herbicide glyphosate disrupts behavior through microbiota-gut-brain axis.

Molecular psychiatry·2026
Same journal

BDNF-DT and BDNF-AS-DT: novel genes in the BDNF locus.

Molecular psychiatry·2026
Same journal

Serotonergic SLC10A4 regulates extracellular serotonin levels and antidepressant responsiveness.

Molecular psychiatry·2026
See all related articles
This summary is machine-generated.

Apolipoprotein A1 (apoA1) is significantly decreased in schizophrenia patients across multiple tissues, including brain and peripheral samples. This finding suggests apoA1 may serve as a potential biomarker for schizophrenia disease mechanisms.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Understanding schizophrenia's molecular etiology is crucial for developing effective treatments.
  • Proteomic profiling offers a promising avenue for identifying disease biomarkers.
  • Previous research has yielded limited molecular insights into schizophrenia.

Purpose of the Study:

  • To identify peripheral and surrogate disease markers for schizophrenia.
  • To investigate the role of apolipoprotein A1 (apoA1) in schizophrenia pathophysiology.
  • To analyze protein expression in cerebrospinal fluid, brain, and peripheral tissues of schizophrenia patients.

Main Methods:

  • Employed high-throughput proteomic techniques (SELDI-TOF mass spectrometry, 2D-DIGE) and traditional methods (ELISA, Western blot).

Related Experiment Videos

  • Analyzed cerebrospinal fluid, liver, red blood cells, serum, and post-mortem brain tissue.
  • Included a cohort of first-onset drug-naive schizophrenia patients to control for antipsychotic treatment effects.

    • Main Results:

    • Apolipoprotein A1 (apoA1) showed consistent downregulation across all five examined tissues in schizophrenia patients compared to controls.
    • Significant reductions in apoA1 were observed in CSF, liver, red blood cells, serum, and brain tissue.
    • Drug-naive patients exhibited an 18% reduction in serum apoA1, supporting its role as a disease marker.

    Conclusions:

    • Apolipoprotein A1 (apoA1) is significantly downregulated in both central nervous system and peripheral tissues of schizophrenia patients.
    • These findings suggest apoA1 may be intrinsically linked to the underlying molecular mechanisms of schizophrenia.
    • ApoA1 represents a potential biomarker for schizophrenia diagnosis and therapeutic development.